FGEN Valuation

FibroGen Inc

Add to Watchlist

Advanced Chart

7.450

+0.22(3.043%)1D

Overview
Forecast
Valuation
Earnings

FGEN Relative Valuation

FGEN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, FGEN is overvalued; if below, it's undervalued.

Historical Valuation

FibroGen Inc (FGEN) is now in the Undervalued zone, suggesting that its current forward PS ratio of 3.18 is considered Undervalued compared with the five-year average of -8.86. The fair price of FibroGen Inc (FGEN) is between 31.07 to 48.16 according to relative valuation methord. Compared to the current price of 7.23 USD , FibroGen Inc is Undervalued By 76.73%.

Relative Value

Fair Zone

31.07-48.16

Current Price：7.23

76.73%

Undervalued

Trailing

Forward

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

-0.13

P/B

Median3y

-5.28

Median5y

-0.42

-249.86

FCF Yield

Median3y

-240.65

Median5y

-144.72

Competitors Valuation Multiple

The average P/S ratio for FGEN's competitors is 63.99, providing a benchmark for relative valuation. FibroGen Inc Corp (FGEN) exhibits a P/S ratio of 3.12, which is -95.13% above the industry average. Given its robust revenue growth of -89.20%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap